BioNexus Gene Lab (BGLC) EPS (Weighted Average and Diluted) (2023 - 2026)

BioNexus Gene Lab has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting -$0.22 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.22, up 35.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.31 (down 255.01% YoY), and the FY2024 annual result was -$0.09, up 45.78% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.22 for Q1 2026 at BioNexus Gene Lab, up from -$0.4 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.61 in Q4 2024 to a low of -$0.75 in Q3 2024.
• The 4-year median for EPS (Weighted Average and Diluted) is -$0.22 (2026), against an average of -$0.15.
• Across the five-year window, EPS (Weighted Average and Diluted) jumped 2673.01% in 2024 and plunged 5683.33% in 2025, its largest moves.
• BioNexus Gene Lab's EPS (Weighted Average and Diluted) stood at $0.02 in 2023, then surged by 2673.01% to $0.61 in 2024, then slumped by 164.33% to -$0.4 in 2025, then jumped by 43.04% to -$0.22 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.22 (Q1 2026), -$0.4 (Q3 2025), and -$0.34 (Q2 2025), per Business Quant data.